|
US4039676A
(en)
|
1975-06-23 |
1977-08-02 |
Ciba-Geigy Corporation |
2-piperidinoalkyl-1,4-benzodioxans
|
|
EP0934941A1
(en)
|
1996-08-09 |
1999-08-11 |
Eisai Co., Ltd. |
Benzopiperidine derivatives
|
|
DE69814012T2
(de)
|
1997-12-19 |
2004-04-01 |
Eli Lilly And Co., Indianapolis |
Hypoglykàmische imidazoline derivate
|
|
GB9905010D0
(en)
|
1999-03-04 |
1999-04-28 |
Merck Sharp & Dohme |
Therapeutic agents
|
|
WO2001017965A2
(en)
|
1999-09-07 |
2001-03-15 |
Syngenta Participations Ag |
Cyanopiperidines as pesticides
|
|
FR2801585B1
(fr)
|
1999-11-25 |
2002-02-15 |
Fournier Ind & Sante |
Nouveaux antagonistes des recepteurs de l'ii-8
|
|
GB0003397D0
(en)
|
2000-02-14 |
2000-04-05 |
Merck Sharp & Dohme |
Therapeutic agents
|
|
CA2424222A1
(en)
|
2000-10-02 |
2002-04-11 |
Merck & Co., Inc. |
Inhibitors of prenyl-protein transferase
|
|
FR2824827B1
(fr)
|
2001-05-17 |
2004-02-13 |
Fournier Lab Sa |
Nouveaux derives de 5-phenyl-1h-indole antagoniste des recepteurs de l'interleukine-8
|
|
FR2824826B1
(fr)
|
2001-05-17 |
2003-11-07 |
Fournier Lab Sa |
Nouveaux derives de 5-cyano-1h-indole antagonistes des recepteurs de l'interleukine-8
|
|
MXPA04004657A
(es)
|
2001-11-14 |
2004-08-13 |
Teva Pharma |
Formas amorfas y cristalinas de potasio de losartan y proceso para su preparacion.
|
|
AU2003237593A1
(en)
*
|
2002-06-05 |
2003-12-22 |
Natco Pharma Limited |
Process for the preparation of 4-(4-fluorobenzoyl) butyric acid
|
|
ATE496893T1
(de)
|
2002-12-20 |
2011-02-15 |
X Ceptor Therapeutics Inc |
Isochinolinonderivate und deren verwendung als medikamente
|
|
CA2537349A1
(en)
|
2003-09-03 |
2005-03-10 |
Galapagos Nv |
The claimed invention relates to novel 4-piperidinecarboxamide and the use thereof for the preparation of medicaments against 5-ht2a receptor-related disorders
|
|
WO2005092854A1
(en)
|
2004-03-03 |
2005-10-06 |
Eli Lilly And Company |
Bicyclic substituted indole-derivative steroid hormone nuclear receptor modulators
|
|
AR048523A1
(es)
|
2004-04-07 |
2006-05-03 |
Kalypsys Inc |
Compuestos con estructura de aril sulfonamida y sulfonilo como moduladores de ppar y metodos para tratar trastornos metabolicos
|
|
AU2006316321A1
(en)
|
2005-11-22 |
2007-05-31 |
Merck & Co., Inc. |
Indole orexin receptor antagonists
|
|
US8222288B2
(en)
|
2006-08-30 |
2012-07-17 |
The Regents Of The University Of Michigan |
Small molecule inhibitors of MDM2 and the uses thereof
|
|
EP2086935A1
(de)
|
2006-10-16 |
2009-08-12 |
Grünenthal GmbH |
Substituierte sulfonamid-derivate als bradykinin 1 rezeptor modulatoren
|
|
EP2097376A2
(en)
|
2006-12-22 |
2009-09-09 |
F. Hoffmann-Roche AG |
Spiro-piperidine derivatives
|
|
WO2008092231A1
(en)
*
|
2007-02-01 |
2008-08-07 |
Resverlogix Corp. |
Compounds for the prevention and treatment of cardiovascular diseases
|
|
EP2020414A1
(en)
|
2007-06-20 |
2009-02-04 |
Laboratorios del Dr. Esteve S.A. |
spiro[piperidine-4,4'-thieno[3,2-c]pyran] derivatives and related compounds as inhibitors of the sigma receptor for the treatment of psychosis
|
|
CN101801965B
(zh)
|
2007-08-17 |
2014-07-30 |
株式会社Lg生命科学 |
作为细胞坏死抑制剂的吲哚化合物
|
|
EP2435407B1
(en)
|
2009-05-29 |
2019-12-25 |
RaQualia Pharma Inc. |
Aryl substituted carboxamide derivatives as calcium or sodium channel blockers
|
|
UA107943C2
(xx)
|
2009-11-16 |
2015-03-10 |
Lilly Co Eli |
Сполуки спіропіперидину як антагоністи рецептора orl-1
|
|
ES2436241T3
(es)
|
2009-11-16 |
2013-12-27 |
Eli Lilly And Company |
Compuestos de espiropiperidina como antagonistas de receptor oral-1
|
|
WO2012025155A1
(en)
|
2010-08-26 |
2012-03-01 |
Novartis Ag |
Hydroxamate-based inhibitors of deacetylases
|
|
BR102012024778A2
(pt)
|
2012-09-28 |
2014-08-19 |
Cristalia Prod Quimicos Farm |
Compostos heteroaromáticos; processo para preparar os compostos, composições farmacêuticas, usos e método de tratamento para as dores aguda e crônica
|
|
US10130632B2
(en)
|
2012-11-27 |
2018-11-20 |
Beth Israel Deaconess Medical Center, Inc. |
Methods for treating renal disease
|
|
JP2016531874A
(ja)
*
|
2013-09-26 |
2016-10-13 |
ファーマケア，インク． |
オートタキシン阻害剤化合物
|
|
ES2895490T3
(es)
|
2014-03-27 |
2022-02-21 |
Acad Medisch Ct |
Iminoazúcares N-(5-(bifen-4-ilmetiloxi)pentil)-sustituidos como inhibidores de glucosilceramida sintasa
|
|
EP3186225A4
(en)
|
2014-08-27 |
2018-02-28 |
The Governing Council of the University of Toronto |
Cannabinoid type 1 receptor modulators
|
|
JP2017536342A
(ja)
|
2014-10-08 |
2017-12-07 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
タンパク質のプレニル化の阻害剤として有用な新規アミノピリジン化合物
|
|
TW201632522A
(zh)
|
2014-11-21 |
2016-09-16 |
伊史帝夫博士實驗室股份有限公司 |
針對疼痛具有多模式活性的螺－異喹啉－１，４’－哌啶化合物
|
|
ES2865199T3
(es)
|
2015-08-27 |
2021-10-15 |
Pfizer |
Compuestos de heteroarilo o arilo condensados bicíclicos como moduladores de IRAK4
|
|
JP6990657B2
(ja)
|
2016-02-08 |
2022-01-13 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
Ｄｄｒ１阻害剤としてのスピロインドリノン
|
|
EP3787669A4
(en)
|
2018-04-30 |
2022-03-30 |
The Trustees of Indiana University |
COMPOUNDS FOR MODULATION OF LEVELS OF DDAH AND ADMA AND METHODS OF USE THEM TO TREAT DISEASES
|
|
MA53924A
(fr)
|
2018-05-22 |
2021-08-25 |
Ionis Pharmaceuticals Inc |
Modulateurs de l'expression d'apol1
|
|
TWI848031B
(zh)
|
2018-12-17 |
2024-07-11 |
美商維泰克斯製藥公司 |
Apol1抑制劑及其使用方法
|
|
US20220144838A1
(en)
|
2019-03-13 |
2022-05-12 |
Nanjing Immunophage Biotech Co., Ltd. |
Compounds as Inhibitors of Macrophage Migration Inhibitory Factor
|
|
TW202136219A
(zh)
|
2019-12-19 |
2021-10-01 |
美商卡司馬療法公司 |
Trpml調節劑
|
|
WO2021154997A1
(en)
|
2020-01-29 |
2021-08-05 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of apol1 and methods of using same
|
|
US20210246121A1
(en)
*
|
2020-02-04 |
2021-08-12 |
Vertex Pharmaceuticals Incorporated |
Solid forms of apol1 inhibitor and methods of using same
|
|
CA3173808A1
(en)
*
|
2020-03-06 |
2021-09-10 |
Vertex Pharmaceuticals Incorporated |
Methods of treating apol-1 dependent focal segmental glomerulosclerosis
|
|
AU2021259580A1
(en)
|
2020-04-22 |
2022-11-24 |
Anima Biotech Inc. |
Collagen 1 translation inhibitors and methods of use thereof
|
|
WO2021220178A1
(en)
|
2020-04-29 |
2021-11-04 |
Cominnex Zrt. |
Iap antagonists and their therapeutic applications
|
|
WO2021224927A1
(en)
|
2020-05-07 |
2021-11-11 |
Rambam Med-Tech Ltd. |
Composition for use in the treatment of apol1-associated disease
|
|
WO2021252863A1
(en)
|
2020-06-12 |
2021-12-16 |
Vertex Pharmaceuticals Incorporated |
Solid forms of apol1 inhibitor and using the same
|
|
WO2021252849A1
(en)
|
2020-06-12 |
2021-12-16 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of apol1 and use of the same
|
|
CA3185604A1
(en)
|
2020-06-12 |
2021-12-16 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of apol1 and use of the same
|
|
IL300298B2
(en)
|
2020-08-26 |
2025-06-01 |
Vertex Pharma |
Inhibitors of apol1 and methods of using same
|
|
MX2024002229A
(es)
|
2021-08-26 |
2024-05-15 |
Vertex Pharma |
Formas solidas de inhibidores de apolipoproteina l1 (apol1) espirotriciclicos y metodos de uso de las mismas.
|
|
CA3240523A1
(en)
|
2021-11-30 |
2023-06-08 |
Vertex Pharmaceuticals Incorporated |
Spirocyclic inhibitors of apol1 and methods of using same
|
|
JP2025505645A
(ja)
|
2022-02-08 |
2025-02-28 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Ａｐｏｌ１の阻害剤としてのスピロピペリジン誘導体およびその使用方法
|
|
EP4476228A1
(en)
|
2022-02-08 |
2024-12-18 |
Vertex Pharmaceuticals Incorporated |
4',5'-dihydrospiro[piperidine-4,7'-thieno[2,3-c]pyran] derivatives as inhibitors of apol1 and methods of using same
|
|
AU2023219516A1
(en)
|
2022-02-08 |
2024-08-22 |
Vertex Pharmaceuticals Incorporated |
2-methyl-4-phenylpiperidin-4-ol derivatives as inhibitors of apol1 and methods of using same
|
|
CN119343353A
(zh)
|
2022-02-08 |
2025-01-21 |
弗特克斯药品有限公司 |
作为APOL1抑制剂的2-甲基-4',5'-二氢螺[哌啶-4,7'-噻吩并[2,3-c]吡喃]衍生物和其使用方法
|